Control

Control Therapeutics is a biotechnology company focused on developing a novel class of medicines that modulate RNA-binding proteins to treat complex diseases. The company's proprietary platform identifies and targets specific RNA-protein interactions to regulate gene expression at the post-transcriptional level. By leveraging deep insights into RNA biology, Control Therapeutics aims to address high-need indications in neurology and oncology where traditional small molecules have failed. The company is currently advancing a pipeline of pre-clinical candidates designed to restore cellular homeostasis by controlling the fate of disease-associated RNAs.